RxDoctor Payments Data

Jared Gilman, MD

Pain Medicine · Tucson, AZNPI 1801240569

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (48.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 38.7% of the total. Reporting peaked in 2020 at $20,127 and has fallen 89.8% since, to $2,062 in 2025. Among pain medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,208in general payments, 2019–2025

Across 488 payments — averaging $82.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$16K
  • Kowa Pharmaceuticals America, Inc.$8K
  • Boston Scientific$7K
  • Nalu Medical, Inc.$4K
  • Abbott$2K
  • Saluda Medical Americas, Inc.$1K
  • plus $3K from 20 others

What the payments were for

  • Speaking & faculty fees$7,00017%
  • Grants$19,30348%
  • Travel & lodging$2,0765%
  • Food & beverage$11,83029%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,208 in reported general payments places this provider in the 90th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$387,246
Medicare patients
543
Services billed
6,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl28$22,928
Buprenorphine43$10,781
Xtampza ErOxycodone Myristate12$6,990
MovantikNaloxegol Oxalate13$5,372
Gabapentin268$3,565
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen120$3,555
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen87$2,964
Oxycodone Hcl180$2,857
Pregabalin117$2,791
Celecoxib24$1,490
Methocarbamol62$1,414
Baclofen81$1,344
Lidocaine13$1,202
Tizanidine Hcl163$1,180
Duloxetine Hcl65$1,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$728$29,91840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →